PR Newswire 科技新闻稿·· 3 小时前AI 评分12
Paradigm Therapeutics 连续第二年入围 2026 Prix Galien USA "Best Start-Up" 奖，候选产品为 SD-101 (Zorblesia™)
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
AI 导读
Paradigm Therapeutics 连续第二年入围 2026 Prix Galien USA "Best Start-Up" 奖，候选产品为治疗大疱性表皮松解症（EB）的局部疗法 SD-101 (Zorblesia™)。
来源：PR Newswire 科技新闻稿 · prnewswire.com